{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"73.800","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"372,671,212","primaryexch":"香港交易所","ric":"6855.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BK9PZW2","am":"165.51","iv":"","ew_strike":"","as":"72.700","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"72.350","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"31.350","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"楊大俊","underlying_ric":"6855.HK","hi52":"95.350","issuer_name":"亞盛醫藥集團 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"71.750","mkt_cap":"27.09","f_aum_hkd":null,"ew_sub_per_to":"","ls":"72.700","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-1.800","aum":"","issued_shares_class_B":null,"vo":"2.28","secondary_listing_flag":false,"listing_date":"2019年10月28日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"亞盛醫藥集團 - B","nm_s":"亞盛醫藥－Ｂ","sym":"6855","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"亞盛醫藥集團是一家主要從事血液系統惡性腫瘤治療藥物發現、研發及商業化的控股公司。該公司主營業務是從事開發及銷售針對腫瘤、乙肝及老化相關的疾病的新型小規模療法。該公司的主要產品包括Olverembatinib（HQP1351）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918等產品。該公司的產品主要用於治療主要血液系統惡性腫瘤，包括慢性粒細胞白血病、急性粒細胞白血病、慢性淋巴細胞白血病、急性淋巴細胞白血病、骨髓增生異常綜合症及多發性骨髓瘤。該公司主要在國內市場開展業務。","op":"72.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港金鐘<br/>金鐘道95號<br/>統一中心<br/>17樓B室","pc":"-2.42","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"74.500","isin":"KYG0519B1023","moneyness":""}},"qid":"1759074103588"}
